Search

Your search keyword '"Craig, Maria E."' showing total 1,018 results
Start Over Author "Craig, Maria E."
1,018 results on '"Craig, Maria E."'

1. Consensus guidance for monitoring individuals with islet autoantibody-positive pre-stage 3 type 1 diabetes

Author

Phillip, Moshe, Achenbach, Peter, Addala, Ananta, Albanese-O’Neill, Anastasia, Battelino, Tadej, Bell, Kirstine J., Besser, Rachel E. J., Bonifacio, Ezio, Colhoun, Helen M., Couper, Jennifer J., Craig, Maria E., Danne, Thomas, de Beaufort, Carine, Dovc, Klemen, Driscoll, Kimberly A., Dutta, Sanjoy, Ebekozien, Osagie, Larsson, Helena Elding, Feiten, Daniel J., Frohnert, Brigitte I., Gabbay, Robert A., Gallagher, Mary P., Greenbaum, Carla J., Griffin, Kurt J., Hagopian, William, Haller, Michael J., Hendrieckx, Christel, Hendriks, Emile, Holt, Richard I. G., Hughes, Lucille, Ismail, Heba M., Jacobsen, Laura M., Johnson, Suzanne B., Kolb, Leslie E., Kordonouri, Olga, Lange, Karin, Lash, Robert W., Lernmark, Åke, Libman, Ingrid, Lundgren, Markus, Maahs, David M., Marcovecchio, M. Loredana, Mathieu, Chantal, Miller, Kellee M., O’Donnell, Holly K., Oron, Tal, Patil, Shivajirao P., Pop-Busui, Rodica, Rewers, Marian J., Rich, Stephen S., Schatz, Desmond A., Schulman-Rosenbaum, Rifka, Simmons, Kimber M., Sims, Emily K., Skyler, Jay S., Smith, Laura B., Speake, Cate, Steck, Andrea K., Thomas, Nicholas P. B., Tonyushkina, Ksenia N., Veijola, Riitta, Wentworth, John M., Wherrett, Diane K., Wood, Jamie R., Ziegler, Anette-Gabriele, and DiMeglio, Linda A.

Published
2024
Full Text
View/download PDF

5. Socioeconomic representativeness of Australian, Canadian and British cohorts from the paediatric diabetes AdDIT study: comparisons to regional and national data

Author

Mahmud, Farid H., Clarke, Antoine B. M., Elia, Yesmino, Curtis, Jacqueline, Benitez-Aguirre, Paul, Cameron, Fergus J., Chiesa, Scott T., Clarson, Cheril, Couper, Jennifer J., Craig, Maria E., Dalton, R. Neil, Daneman, Denis, Davis, Elizabeth A., Deanfield, John E., Donaghue, Kim C., Jones, Timothy W., Marshall, Sally M., Neil, Andrew, and Marcovecchio, M. Loredana

Published
2023
Full Text
View/download PDF

7. IL-6 receptor blockade does not slow β cell loss in new-onset type 1 diabetes

Author

Greenbaum, Carla J, Serti, Elisavet, Lambert, Katharina, Weiner, Lia J, Kanaparthi, Sai, Lord, Sandra, Gitelman, Stephen E, Wilson, Darrell M, Gaglia, Jason L, Griffin, Kurt J, Russell, William E, Raskin, Philip, Moran, Antoinette, Willi, Steven M, Tsalikian, Eva, DiMeglio, Linda A, Herold, Kevan C, Moore, Wayne V, Goland, Robin, Harris, Mark, Craig, Maria E, Schatz, Desmond A, Baidal, David A, Rodriguez, Henry, Utzschneider, Kristina M, Nel, Hendrik J, Soppe, Carol L, Boyle, Karen D, Cerosaletti, Karen, Keyes-Elstein, Lynette, Long, S Alice, Thomas, Ranjeny, McNamara, James G, Buckner, Jane H, and Sanda, Srinath

Subjects
Diabetes, Clinical Research, Clinical Trials and Supportive Activities, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Metabolic and endocrine, Good Health and Well Being, Adolescent, B-Lymphocyte Subsets, Child, Diabetes Mellitus, Type 1, Double-Blind Method, Female, Humans, Male, Receptors, Interleukin-6, ITN058AI EXTEND Study Team, Beta cells, Endocrinology, Immunology, T cells
Abstract

BackgroundIL-6 receptor (IL-6R) signaling drives development of T cell populations important to type 1 diabetes pathogenesis. We evaluated whether blockade of IL-6R with monoclonal antibody tocilizumab would slow loss of residual β cell function in newly diagnosed type 1 diabetes patients.MethodsWe conducted a multicenter, randomized, placebo-controlled, double-blind trial with tocilizumab in new-onset type 1 diabetes. Participants were screened within 100 days of diagnosis. Eligible participants were randomized 2:1 to receive 7 monthly doses of tocilizumab or placebo. The primary outcome was the change from screening in the mean AUC of C-peptide collected during the first 2 hours of a mixed meal tolerance test at week 52 in pediatric participants (ages 6-17 years).ResultsThere was no statistical difference in the primary outcome between tocilizumab and placebo. Immunophenotyping showed reductions in downstream signaling of the IL-6R in T cells but no changes in CD4 memory subsets, Th17 cells, Tregs, or CD4+ T effector cell resistance to Treg suppression. A DC subset decreased during therapy but regressed to baseline once therapy stopped. Tocilizumab was well tolerated.ConclusionTocilizumab reduced T cell IL-6R signaling but did not modulate CD4+ T cell phenotypes or slow loss of residual β cell function in newly diagnosed individuals with type 1 diabetes.Trial RegistrationClinicalTrials.gov NCT02293837.FundingNIH National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and National Institute of Allergy and Infectious Diseases (NIAID) UM1AI109565, UL1TR000004 from NIH/National Center for Research Resources (NCRR) Clinical and Translational Science Award (CTSA), NIH/NIDDK P30DK036836, NIH/NIDDK U01DK103266, NIH/NIDDK U01DK103266, 1UL1TR000064 from NIH/NCRR CTSA, NIH/National Center for Advancing Translational Sciences (NCATS) UL1TR001878, UL1TR002537 from NIH/CTSA; National Health and Medical Research Council Practitioner Fellowship (APP1136735), NIH/NIDDK U01-DK085476, NIH/CTSA UL1-TR002494, Indiana Clinical and Translational Science Institute Award UL1TR002529, Vanderbilt Institute for Clinical and Translational Research UL1TR000445. NIH/NCATS UL1TR003142, NIH/CTSA program UL1-TR002494, Veteran Affairs Administration, and 1R01AI132774.

Published
2021

16. Urinary albumin/creatinine ratio tertiles predict risk of diabetic retinopathy progression: a natural history study from the Adolescent Cardio-Renal Intervention Trial (AdDIT) observational cohort

Author

Benitez-Aguirre, Paul Z., Marcovecchio, M. Loredana, Chiesa, Scott T., Craig, Maria E., Wong, Tien Y., Davis, Elizabeth A., Cotterill, Andrew, Couper, Jenny J., Cameron, Fergus J., Mahmud, Farid H., Neil, H. Andrew W., Jones, Timothy W., Hodgson, Lauren A. B., Dalton, R. Neil, Marshall, Sally M., Deanfield, John, Dunger, David B., and Donaghue, Kim C.

Published
2022
Full Text
View/download PDF

17. Circulation of enterovirus D68 (EV-D68) causing respiratory illness in New South Wales, Australia, between August 2018 and November 2019

Author

Stelzer-Braid, Sacha, Yeang, Malinna, Britton, Philip N., Kim, Ki Wook, Varadhan, Hemalatha, Andrews, Peter Ian, Briest, Romain, Branley, James, Balgahom, Rifky, Burrell, Rebecca, Gehrig, Nicole, Newcombe, James, Kesson, Alison, Kok, Jen, Maley, Michael, Van Hal, Sebastiaan, MacIntyre, C. Raina, Craig, Maria E., Ferson, Mark J., and Rawlinson, William D.

Published
2022
Full Text
View/download PDF

18. Women with type 1 diabetes exhibit a progressive increase in gut Saccharomyces cerevisiae in pregnancy associated with evidence of gut inflammation

Author

Bandala-Sanchez, Esther, Roth-Schulze, Alexandra J., Oakey, Helena, Penno, Megan A.S., Bediaga, Naiara G., Naselli, Gaetano, Ngui, Katrina M., Smith, Alannah D., Huang, Dexing, Zozaya-Valdes, Enrique, Thomson, Rebecca L., Brown, James D., Vuillermin, Peter J., Barry, Simon C., Craig, Maria E., Rawlinson, William D., Davis, Elizabeth A., Harris, Mark, Soldatos, Georgia, Colman, Peter G., Wentworth, John M., Haynes, Aveni, Morahan, Grant, Sinnott, Richard O., Papenfuss, Anthony T., Couper, Jennifer J., and Harrison, Leonard C.

Published
2022
Full Text
View/download PDF

21. Blood pressure postpartum (BP2) RCT protocol: Follow-up and lifestyle behaviour change strategies in the first 12 months after hypertensive pregnancy

Author

Henry, Amanda, Arnott, Clare, Makris, Angela, Davis, Gregory, Hennessy, Annemarie, Beech, Amanda, Pettit, Franziska, SE Homer, Caroline, Craig, Maria E., Roberts, Lynne, Hyett, Jon, Chambers, Georgina, Fitzgerald, Oisin, Gow, Megan, Mann, Linda, Challis, Daniel, Gale, Marianne, Ruhotas, Annette, Kirwin, Emilee, Denney-Wilson, Elizabeth, and Brown, Mark

Published
2020
Full Text
View/download PDF

22. Demographic, Clinical, Management, and Outcome Characteristics of 8,004 Young Children With Type 1 Diabetes.

Author

Sandy, Jessica L., Tittel, Sascha R., Rompicherla, Saketh, Karges, Beate, James, Steven, Rioles, Nicole, Zimmerman, Anthony G., Fröhlich-Reiterer, Elke, Maahs, David M., Lanzinger, Stefanie, Craig, Maria E., Ebekozien, Osagie, Craig, Maria, Colman, Peter, Glastras, Sarah, Jones, Tim, Johnson, Stephanie, Sinnott, Richard, Zimmerman, Anthony, and Anderson, Kym

Subjects
TYPE 1 diabetes, CONTINUOUS glucose monitoring, INSULIN pumps, INSULIN therapy, HYPERGLYCEMIA, DIAGNOSIS of diabetes
Abstract

OBJECTIVE: To compare demographic, clinical, and therapeutic characteristics of children with type 1 diabetes age <6 years across three international registries: Diabetes Prospective Follow-Up Registry (DPV; Europe), T1D Exchange Quality Improvement Network (T1DX-QI; U.S.), and Australasian Diabetes Data Network (ADDN; Australasia). RESEARCH DESIGN AND METHODS: An analysis was conducted comparing 2019–2021 prospective registry data from 8,004 children. RESULTS: Mean ± SD ages at diabetes diagnosis were 3.2 ± 1.4 (DPV and ADDN) and 3.7 ± 1.8 years (T1DX-QI). Mean ± SD diabetes durations were 1.4 ± 1.3 (DPV), 1.4 ± 1.6 (T1DX-QI), and 1.5 ± 1.3 years (ADDN). BMI z scores were in the overweight range in 36.2% (DPV), 41.8% (T1DX-QI), and 50.0% (ADDN) of participants. Mean ± SD HbA1c varied among registries: DPV 7.3 ± 0.9% (56 ± 10 mmol/mol), T1DX-QI 8.0 ± 1.4% (64 ± 16 mmol/mol), and ADDN 7.7 ± 1.2% (61 ± 13 mmol/mol). Overall, 37.5% of children achieved the target HbA1c of <7.0% (53 mmol/mol): 43.6% in DPV, 25.5% in T1DX-QI, and 27.5% in ADDN. Use of diabetes technologies such as insulin pump (DPV 86.6%, T1DX 46.6%, and ADDN 39.2%) and continuous glucose monitoring (CGM; DPV 85.1%, T1DX-QI 57.6%, and ADDN 70.5%) varied among registries. Use of hybrid closed-loop (HCL) systems was uncommon (from 0.5% [ADDN] to 6.9% [DPV]). CONCLUSIONS: Across three major registries, more than half of children age <6 years did not achieve the target HbA1c of <7.0% (53 mmol/mol). CGM was used by most participants, whereas insulin pump use varied across registries, and HCL system use was rare. The differences seen in glycemia and use of diabetes technologies among registries require further investigation to determine potential contributing factors and areas to target to improve the care of this vulnerable group. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

26. The MothersBabies Study, an Australian Prospective Cohort Study Analyzing the Microbiome in the Preconception and Perinatal Period to Determine Risk of Adverse Pregnancy, Postpartum, and Child-Related Health Outcomes: Study Protocol

Author

Strout, Naomi, primary, Pasic, Lana, additional, Hicks, Chloe, additional, Chua, Xin-Yi, additional, Tashvighi, Niki, additional, Butler, Phoebe, additional, Liu, Zhixin, additional, El-Assaad, Fatima, additional, Holmes, Elaine, additional, Susic, Daniella, additional, Samaras, Katherine, additional, Craig, Maria E., additional, Davis, Gregory K., additional, Henry, Amanda, additional, Ledger, William L., additional, and El-Omar, Emad M., additional

Published
2023
Full Text
View/download PDF

28. Denisovan, modern human and mouse TNFAIP3 alleles tune A20 phosphorylation and immunity

Author

Zammit, Nathan W., Siggs, Owen M., Gray, Paul E., Horikawa, Keisuke, Langley, David B., Walters, Stacey N., Daley, Stephen R., Loetsch, Claudia, Warren, Joanna, Yap, Jin Yan, Cultrone, Daniele, Russell, Amanda, Malle, Elisabeth K., Villanueva, Jeanette E., Cowley, Mark J., Gayevskiy, Velimir, Dinger, Marcel E., Brink, Robert, Zahra, David, Chaudhri, Geeta, Karupiah, Gunasegaran, Whittle, Belinda, Roots, Carla, Bertram, Edward, Yamada, Michiko, Jeelall, Yogesh, Enders, Anselm, Clifton, Benjamin E., Mabbitt, Peter D., Jackson, Colin J., Watson, Susan R., Jenne, Craig N., Lanier, Lewis L., Wiltshire, Tim, Spitzer, Matthew H., Nolan, Garry P., Schmitz, Frank, Aderem, Alan, Porebski, Benjamin T., Buckle, Ashley M., Abbott, Derek W., Ziegler, John B., Craig, Maria E., Benitez-Aguirre, Paul, Teo, Juliana, Tangye, Stuart G., King, Cecile, Wong, Melanie, Cox, Murray P., Phung, Wilson, Tang, Jia, Sandoval, Wendy, Wertz, Ingrid E., Christ, Daniel, Goodnow, Christopher C., and Grey, Shane T.

Published
2019
Full Text
View/download PDF

30. Reasons for hospitalisation in youth with type 1 diabetes, 2010–2019.

Author

Tomic, Dunya, Craig, Maria E., Magliano, Dianna J., and Shaw, Jonathan E.

Subjects
*DIABETES complications, *RELATIVE medical risk, *CONFIDENCE intervals, *TYPE 1 diabetes, *SOCIOECONOMIC factors, *HOSPITAL care, *RESEARCH funding, *DESCRIPTIVE statistics, *LOGISTIC regression analysis, *POISSON distribution, *DIABETIC acidosis, *DISEASE risk factors, *ADOLESCENCE
Abstract

Aims: To determine the incidence of hospitalisation for all diagnoses among Australian youth with type 1 diabetes. Methods: We linked Australians aged under 20 years with type 1 diabetes on the National Diabetes Services Scheme (n = 45,685) to hospital admission data from 2010 to 2019. We determined relative risks (RR) of hospitalisation among those with type 1 diabetes in the states of Victoria and Queensland (n = 21,898) compared to the general population for 2010–2017 using Poisson regression. Results: Australian youth with type 1 diabetes had increased risk for almost all reasons for hospitalisation compared to the general population, especially infections such as anogenital herpesviral infections (RR 54.83, 95% CI 33.21–90.53), and mental health disorders including personality disorders (RR 9.70, 95% CI 8.02–11.72). Among those with type 1 diabetes, over 60% of hospitalisations were directly related to diabetes, almost half of which were for ketoacidosis. Approximately 15% of ketoacidosis admissions occurred within 3 months of diabetes diagnosis. One quarter of those with admissions for ketoacidosis were readmitted for ketoacidosis within 12 months. Residence in areas of high socio‐economic disadvantage was an independent risk factor for admission and readmission for ketoacidosis. Conclusions: Youth with type 1 diabetes are susceptible to a wide range of complications. Clinicians should consider screening and prevention for conditions such as infections and mental health disorders. Targeted support and education around glycaemic management should be considered in those at high risk for ketoacidosis admission including those living in areas of high socio‐economic disadvantage. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

31. Protocol for a nested case-control study design for omics investigations in the Environmental Determinants of Islet Autoimmunity cohort.

Author

Oakey, Helena, Giles, Lynne C., Thomson, Rebecca L., Lê Cao, Kim-Anh, Ashwood, Pat, Brown, James D., Knight, Emma J., Barry, Simon C., Craig, Maria E., Colman, Peter G., Davis, Elizabeth A., Hamilton-Williams, Emma E., Harrison, Leonard C., Haynes, Aveni, Kim, Ki Wook, Mallitt, Kylie-Ann, McGorm, Kelly, Morahan, Grant, Rawlinson, William D., and Sinnott, Richard O.

Subjects
EXPERIMENTAL design, AUTOIMMUNITY, PANEL analysis, CASE-control method, TYPE 1 diabetes, CELIAC disease
Abstract

Background: The Environmental Determinants of Islet Autoimmunity (ENDIA) pregnancy-birth cohort investigates the developmental origins of type 1 diabetes (T1D), with recruitment between 2013 and 2019. ENDIA is the first study in the world with comprehensive data and biospecimen collection during pregnancy, at birth and through childhood from at-risk children who have a first-degree relative with T1D. Environmental exposures are thought to drive the progression to clinical T1D, with pancreatic islet autoimmunity (IA) developing in genetically susceptible individuals. The exposures and key molecular mechanisms driving this progression are unknown. Persistent IA is the primary outcome of ENDIA; defined as a positive antibody for at least one of IAA, GAD, ZnT8 or IA2 on two consecutive occasions and signifies high risk of clinical T1D. Method: A nested case-control (NCC) study design with 54 cases and 161 matched controls aims to investigate associations between persistent IA and longitudinal omics exposures in ENDIA. The NCC study will analyse samples obtained from ENDIA children who have either developed persistent IA or progressed to clinical T1D (cases) and matched control children at risk of developing persistent IA. Control children were matched on sex and age, with all four autoantibodies absent within a defined window of the case's onset date. Cases seroconverted at a median of 1.37 years (IQR 0.95, 2.56). Longitudinal omics data generated from approximately 16,000 samples of different biospecimen types, will enable evaluation of changes from pregnancy through childhood. Conclusions: This paper describes the ENDIA NCC study, omics platform design considerations and planned univariate and multivariate analyses for its longitudinal data. Methodologies for multivariate omics analysis with longitudinal data are discovery-focused and data driven. There is currently no single multivariate method tailored specifically for the longitudinal omics data that the ENDIA NCC study will generate and therefore omics analysis results will require either cross validation or independent validation. The ENDIA nested case-control study will utilize longitudinal omics data on approximately 16,000 samples from 190 unique children at risk of type 1 diabetes (T1D), including 54 who have developed islet autoimmunity (IA), followed during pregnancy, at birth and during early childhood, enabling the developmental origins of T1D to be explored. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

39. The Adolescent Cardio-Renal Intervention Trial (AdDIT): retinal vascular geometry and renal function in adolescents with type 1 diabetes

Author

Benitez-Aguirre, Paul Z., Wong, Tien Y., Craig, Maria E., Davis, Elizabeth A., Cotterill, Andrew, Couper, Jennifer J., Cameron, Fergus J., Mahmud, Farid H., Jones, Tim W., Hodgson, Lauren A. B., Dalton, R. Neil, Dunger, David B., Donaghue, Kim C., Marshall, Sally, Armitage, Jane, Bingley, Polly, Van’t Hoff, William, Dunger, David, Dalton, R. Neil, Daneman, Denis, Neil, Andrew, Deanfield, John, Jones, Tim, Donaghue, Kim, Jones, Tim, Donaghue, Kim, Craig, Maria, Benitez-Aguirre, Paul, Cameron, Fergus, Couper, Jennifer, Davis, Elizabeth, Cotterill, Andrew, Verge, Charles, Bergman, Phil, Rodda, Christine, Marcovecchio, M. Loredana, Deanfield, John, Chiesa, Scott, Acerini, Carlo, Ackland, Fran, Anand, Binu, Barrett, Tim, Birrell, Virginia, Campbell, Fiona, Charakida, Marietta, Cheetham, Tim, Cooper, Chris, Doughty, Ian, Dutta, Atanu, Edge, Julie, Gray, Alastair, Hamilton-Shield, Julian, Heywood, James, Leech, Nicola, Mann, Nick, Parker, Richard, Rayman, Gerry, Robinson, Jonathon Mark, Russell-Taylor, Michelle, Sankar, Vengudi, Smith, Anne, Thalange, Nandu, Wilson, Mark, Yaliwal, Chandan, Mahmud, Farid, Clarson, Cheril, Curtis, Jacqueline, Daneman, Denis, Sochett, Etienne, The Adolescent Type 1 Diabetes Cardio-Renal Intervention Trial (AdDIT), AdDIT investigators in Australia, AdDIT investigators in the UK, and AdDIT investigators in Canada

Published
2018
Full Text
View/download PDF

44. Genome-wide association study of longitudinal urinary albumin excretion in patients with type 1 diabetes

Author

Hutchinson, Anna M, primary, Chen, Wei-Min, additional, Onengut-Gumuscu, Suna, additional, Benitez-Aguirre, Paul, additional, Cameron, Fergus J, additional, Chiesa, Scott T, additional, Couper, Jennifer J, additional, Craig, Maria E, additional, Dalton, Neil R., additional, Daneman, Denis, additional, Davis, Elizabeth A, additional, Deanfield, John E, additional, Donaghue, Kim C, additional, Jones, Timothy W, additional, Mahmud, Farid H, additional, Marshall, Sally M, additional, Neil, Andrew, additional, Rich, Stephen S, additional, Marcovecchio, M. Loredana, additional, and Wallace, Chris, additional

Published
2022
Full Text
View/download PDF

45. Improved local diagnosis of focal hyperinsulinism in the COVID‐19 era by interstate radiopharmaceutical transport

Author

Vanderniet, Joel, primary, Neville, Kristen A, additional, Conwell, Louise S, additional, Wegner, Eva A, additional, Craig, Maria E, additional, Adams, Susan, additional, Gifford, Andrew J, additional, Koutsiofi, Melissa, additional, Calabria, Frances M, additional, Maguire, Gemma, additional, Thomas, Paul, additional, Campbell, Louise, additional, and Woodhead, Helen J, additional

Published
2022
Full Text
View/download PDF

46. Diabetic Ketoacidosis at Onset of Type 1 Diabetes and Long-term HbA1c in 7,961 Children and Young Adults in the Australasian Diabetes Data Network

Author

Clapin, Helen F, primary, Earnest, Arul, primary, Colman, Peter G, primary, Davis, Elizabeth A, primary, Jefferies, Craig, primary, Anderson, Kym, primary, Chee, Melissa, primary, Bergmann, Philip, primary, Bock, Martin de, primary, Kao, Kung-Ting, primary, Fegan, P Gerry, primary, Holmes-Walker, D Jane, primary, Johnson, Stephanie, primary, King, Bruce R, primary, Mok, Meng Tuck, primary, Narayan, Kruthika, primary, Vargas, Alexia S Peña, primary, SINNOTT, RICHARD, primary, Wheeler, Benjamin J, primary, Zimmermann, Anthony, primary, Craig, Maria E., primary, Couper, Jenny J, primary, and group, the ADDN Study, primary

Published
2022
Full Text
View/download PDF

48. ISPAD Clinical Practice Consensus Guidelines 2022: Management of the child, adolescent, and young adult with diabetes in limited resource settings

Author

Virmani, Anju, primary, Brink, Stuart J., additional, Middlehurst, Angela, additional, Mohsin, Fauzia, additional, Giraudo, Franco, additional, Sarda, Archana, additional, Ajmal, Sana, additional, von Oettingen, Julia E., additional, Pillay, Kuben, additional, Likitmaskul, Supawadee, additional, Calliari, Luis Eduardo, additional, and Craig, Maria E., additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results